Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy - PubMed (original) (raw)

Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy

E Mejstríková et al. Leukemia. 2005 Jun.

No abstract available

PubMed Disclaimer

Similar articles

• Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.
  Piccaluga PP, Arpinati M, Candoni A, Laterza C, Paolini S, Gazzola A, Sabattini E, Visani G, Pileri SA. Piccaluga PP, et al. Leuk Lymphoma. 2011 Feb;52(2):325-7. doi: 10.3109/10428194.2010.529206. Epub 2010 Nov 15. Leuk Lymphoma. 2011. PMID: 21077738 No abstract available.
• [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
  Meng FY, Fu YB. Meng FY, et al. Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):441-3. Zhonghua Yi Xue Za Zhi. 2005. PMID: 15854546 Chinese. No abstract available.
• Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
  Raponi S, De Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, Perbellini O, Pizzolo G, Foá R, Guarini A. Raponi S, et al. Leuk Lymphoma. 2011 Jun;52(6):1098-107. doi: 10.3109/10428194.2011.559668. Epub 2011 Feb 24. Leuk Lymphoma. 2011. PMID: 21348573
• Immunotherapy for acute leukemias.
  Caron PC, Scheinberg DA. Caron PC, et al. Curr Opin Oncol. 1994 Jan;6(1):14-22. doi: 10.1097/00001622-199401000-00003. Curr Opin Oncol. 1994. PMID: 8204688 Review.
• [Monoclonal antibody therapies for acute leukemia].
  Takeshita A, Ono R. Takeshita A, et al. Rinsho Ketsueki. 2002 May;43(5):353-6. Rinsho Ketsueki. 2002. PMID: 12096485 Review. Japanese. No abstract available.

Cited by

• The intriguing roles of Siglec family members in the tumor microenvironment.
  Jiang KY, Qi LL, Kang FB, Wang L. Jiang KY, et al. Biomark Res. 2022 Apr 13;10(1):22. doi: 10.1186/s40364-022-00369-1. Biomark Res. 2022. PMID: 35418152 Free PMC article. Review.
• CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
  Reusing SB, Vallera DA, Manser AR, Vatrin T, Bhatia S, Felices M, Miller JS, Uhrberg M, Babor F. Reusing SB, et al. Cancer Immunol Immunother. 2021 Dec;70(12):3701-3708. doi: 10.1007/s00262-021-03008-0. Epub 2021 Aug 16. Cancer Immunol Immunother. 2021. PMID: 34398302 Free PMC article.
• High-Dimensional Analysis of Single-Cell Flow Cytometry Data Predicts Relapse in Childhood Acute Lymphoblastic Leukaemia.
  Chulián S, Martínez-Rubio Á, Pérez-García VM, Rosa M, Blázquez Goñi C, Rodríguez Gutiérrez JF, Hermosín-Ramos L, Molinos Quintana Á, Caballero-Velázquez T, Ramírez-Orellana M, Castillo Robleda A, Fernández-Martínez JL. Chulián S, et al. Cancers (Basel). 2020 Dec 23;13(1):17. doi: 10.3390/cancers13010017. Cancers (Basel). 2020. PMID: 33374500 Free PMC article.
• Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy.
  Wielgat P, Rogowski K, Niemirowicz-Laskowska K, Car H. Wielgat P, et al. Int J Mol Sci. 2020 Jun 19;21(12):4361. doi: 10.3390/ijms21124361. Int J Mol Sci. 2020. PMID: 32575400 Free PMC article. Review.
• CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo.
  Reimer J, Knöß S, Labuhn M, Charpentier EM, Göhring G, Schlegelberger B, Klusmann JH, Heckl D. Reimer J, et al. Haematologica. 2017 Sep;102(9):1558-1566. doi: 10.3324/haematol.2017.164046. Epub 2017 Jun 1. Haematologica. 2017. PMID: 28572162 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations